Literature DB >> 3141160

Inactivation of human immunodeficiency virus in serum specimens as a safety measure for diagnostic immunoassays.

P Ukkonen1, J Korpela, J Suni, K Hedman.   

Abstract

Since the human immunodeficiency virus (HIV) may be transmitted accidentally to laboratory personnel analyzing patient sera, the efficiency of a non-ionic detergent, Triton X-100, in inactivation of HIV in human serum as a safety measure was studied. Semliki Forest virus, an enveloped toga virus, was used as a model virus to create optimal treatment conditions. In the presence of 50% serum, complete inactivation (i.e. no residual virus detected, greater than 7 log reduction of virus titre) was achieved by incubation with 0.2% Triton X-100 for 1 h at 37 degrees C. Under these conditions HIV was also completely inactivated (i.e. no residual infectious virus detected, greater than or equal to 5 log reduction of virus titre). Both treated and untreated serum specimens were also tested with several enzyme immunoassays used in virological laboratories to determine whether the inactivation treatment interfered with the assays. The treated specimens, further diluted as recommended for each assay, were subjected to 15 enzyme immunoassays for microbial antibodies and antigens (HIV IgG, hepatitis A IgG and IgM, hepatitis B s, c, and e antigens and antibodies, cytomegalovirus IgG, mumps virus IgG, poliovirus IgG, rubellavirus IgM, toxoplasma IgG, and chlamydia IgG). Clearly decreased sensitivity was found only with two hepatitis B tests (e antigen and antibody to the surface antigen). It is concluded that safe inactivation of HIV in serum is achieved by 0.2% Triton X-100, but the treatment may decrease the sensitivity of some tests in which low specimen dilution is used.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141160     DOI: 10.1007/bf01962603

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

1.  Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.

Authors:  L Resnick; K Veren; S Z Salahuddin; S Tondreau; P D Markham
Journal:  JAMA       Date:  1986-04-11       Impact factor: 56.272

2.  Effect of using heat-inactivated serum with the Abbott human T-cell lymphotropic virus type III antibody test.

Authors:  D L Jungkind; S A DiRenzo; S J Young
Journal:  J Clin Microbiol       Date:  1986-02       Impact factor: 5.948

3.  Heat inactivation of serum may interfere with tests for antibodies to LAV/HTLV-III.

Authors:  D van Beers; M Duys; M Maes; D Biarent; D Haumont
Journal:  J Virol Methods       Date:  1985-12       Impact factor: 2.014

4.  Lab worker infected with AIDS virus.

Authors:  J Palca
Journal:  Nature       Date:  1987 Sep 10-16       Impact factor: 49.962

5.  Safety issues raised by worker's infection with AIDS virus.

Authors:  J Palca
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

6.  The binding of detergents to lipophilic and hydrophilic proteins.

Authors:  A Helenius; K Simons
Journal:  J Biol Chem       Date:  1972-06-10       Impact factor: 5.157

7.  Disinfectant inactivation of AIDS virus in blood or serum.

Authors:  A M Wallbank
Journal:  Lancet       Date:  1985-03-16       Impact factor: 79.321

8.  Detection of poliovirus antigen by enzyme immunoassay.

Authors:  P Ukkonen; A Huovilainen; T Hovi
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

9.  Enzyme-linked immunosorbent assay for mumps and parainfluenza type 1 immunoglobulin G and immunoglobulin M antibodies.

Authors:  P Ukkonen; O Väisänen; K Penttinen
Journal:  J Clin Microbiol       Date:  1980-04       Impact factor: 5.948

10.  Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.

Authors:  J S McDougal; L S Martin; S P Cort; M Mozen; C M Heldebrant; B L Evatt
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

View more
  6 in total

1.  Effective chemical virus inactivation of patient serum compatible with accurate serodiagnosis of infections.

Authors:  M M Remy; M Alfter; M-N Chiem; M T Barbani; O B Engler; F Suter-Riniker
Journal:  Clin Microbiol Infect       Date:  2018-10-28       Impact factor: 8.067

2.  'BhAVI-23'-A spice-herb based dietary infusion possessing in-vitro anti-viral potential.

Authors:  Sudhanshu Saxena; Sanjeev Kumar; Sachin N Hajare; Sumit Gupta; Satyendra Gautam; Sunil K Ghosh
Journal:  J Ayurveda Integr Med       Date:  2021-01-04

3.  Impact of ASFV Detergent Inactivation on Biomarkers in Serum and Saliva Samples.

Authors:  Lorena Franco-Martínez; Martin Beer; Silvia Martínez-Subiela; Edgar García-Manzanilla; Sandra Blome; Tessa Carrau
Journal:  Pathogens       Date:  2022-06-30

4.  Experimental Evaluation of an Interferometric Light Microscopy Particle Counter for Titering and Characterization of Virus Preparations.

Authors:  Vesa Turkki; Elisa Alppila; Seppo Ylä-Herttuala; Hanna P Lesch
Journal:  Viruses       Date:  2021-05-19       Impact factor: 5.048

5.  Structural Basis of 2-Phenylamino-4-phenoxyquinoline Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.

Authors:  Arthit Makarasen; Suwicha Patnin; Pongsit Vijitphan; Nanthawan Reukngam; Panita Khlaychan; Mayuso Kuno; Pakamas Intachote; Busakorn Saimanee; Suchada Sengsai; Supanna Techasakul
Journal:  Molecules       Date:  2022-01-11       Impact factor: 4.411

6.  Supported Lipid Bilayer Platform for Characterizing the Membrane-Disruptive Behaviors of Triton X-100 and Potential Detergent Replacements.

Authors:  Negin Gooran; Bo Kyeong Yoon; Joshua A Jackman
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.